Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017469 | 0.85 | MAPK1 (0.64) | NPC1SMN1; SMN2RAB9AAPPMAPK1 | |
| SCHEMBL16681966 | 0.80 | MAPT (0.52) | SMN1; SMN2RAB9AAPPMAPK1HPGD | |
| SCHEMBL5532773 | 0.78 | KMT2A (0.60) | SMN1; SMN2RAB9AMAPK1KMT2AMAPT | |
| SCHEMBL11212235 | 0.78 | TP53 (0.55) | SMN1; SMN2MAPK1KMT2AMAPTMEN1 | |
| SCHEMBL11554638 | 0.78 | MEN1 (0.66) | NPC1SMN1; SMN2RAB9AAPPMAPK1 | |
| SCHEMBL4777988 | 0.78 | LMNA (0.72) | NPC1SMN1; SMN2RAB9AKMT2AMAPT | |
| SCHEMBL6814984 | 0.76 | SMN1; SMN2 (0.58) | NPC1SMN1; SMN2RAB9AKMT2AMAPT | |
| SCHEMBL655613 | 0.76 | CYP3A4 (0.56) | APPALDH1A1CYP3A4LMNATP53 | |
| SCHEMBL5699237 | 0.76 | CYP3A4 (0.50) | APPMAPK1CYP3A4LMNA | |
| SCHEMBL18611543 | 0.76 | MAPT (0.46) | NPC1SMN1; SMN2RAB9AAPPAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150126504-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20120283219-A1 | DIAMINOPTERIDINE DERIVATIVES | BIORELIX, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120283219-A1 | DIAMINOPTERIDINE DERIVATIVES | BIORELIX, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120283219-A1 | DIAMINOPTERIDINE DERIVATIVES | BIORELIX, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | disclosed |
| EP-2410856-A1 | DIAMINOPTERIDINE DERIVATIVES | Biorelix, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-1471915-B1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010110907-A1 | DIAMINOPTERIDINE DERIVATIVES | BIORELIX, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010110907-A1 | DIAMINOPTERIDINE DERIVATIVES | BIORELIX, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283219-A1 | DIAMINOPTERIDINE DERIVATIVES | MPO, AOC1, DCTD | NPC1 1268/4885SMN1; SMN2 3511/4885RAB9A 3131/4885 |
| US-20150126504-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | FCER2, FCGR1A, FCGR2A | NPC1 3266/4885SMN1; SMN2 4764/4885RAB9A 2531/4885 |
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | GLRB, GRIN2B, GLRA2 | NPC1 215/4885SMN1; SMN2 508/4885RAB9A 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.